<SEC-DOCUMENT>0001193125-17-335068.txt : 20171107
<SEC-HEADER>0001193125-17-335068.hdr.sgml : 20171107
<ACCEPTANCE-DATETIME>20171107080033
ACCESSION NUMBER:		0001193125-17-335068
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171107
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171107
DATE AS OF CHANGE:		20171107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRISPR Therapeutics AG
		CENTRAL INDEX KEY:			0001674416
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				473173478
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37923
		FILM NUMBER:		171181147

	BUSINESS ADDRESS:	
		STREET 1:		BAARERSTRASSE 14
		CITY:			ZUG
		STATE:			V8
		ZIP:			CH-6300
		BUSINESS PHONE:		6173154600

	MAIL ADDRESS:	
		STREET 1:		BAARERSTRASSE 14
		CITY:			ZUG
		STATE:			V8
		ZIP:			CH-6300
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d489475d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): November&nbsp;7, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CRISPR THERAPEUTICS AG </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Company as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Switzerland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-37923</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Baarerstrasse 14 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6300 Zug </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Switzerland
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>+41 61 228 7800 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the
Securities Exchange Act of 1934. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;7, 2017, CRISPR Therapeutics AG (the &#147;Company&#148;) issued a press release announcing that the Company will present data on November 10,
2017 at 6:00 PM eastern at the Society for Immunotherapy of Cancer (&#147;SITC&#148;) 32<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Annual Conference. A live webcast of the presentation, and the presentation materials, can be accessed
under &#147;Events&nbsp;&amp; Presentations&#148; in the Investors&nbsp;&amp; Media section of the Company&#146;s website at www.crisprtx.com. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d489475dex991.htm">Press Release by CRISPR Therapeutics AG, dated November 7, 2017 </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">CRISPR THERAPEUTICS AG</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;7, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Samarth Kulkarni</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Samarth Kulkarni, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Business Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d489475dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g489475g84u85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor
Reception at the 32<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Annual Society for Immunotherapy of Cancer Meeting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZUG, Switzerland and
CAMBRIDGE, Mass., November&nbsp;7, 2017 &#151; CRISPR Therapeutics (NASDAQ: CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that the Company will present a poster on CRISPR&#146;s
Allogeneic CRISPR-based CAR-T cell therapy directed at CD19-positive malignancies at the 32nd Annual Society for Immunotherapy of Cancer Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CRISPR
Therapeutics will also host an investor reception to highlight its immune-oncology research and development strategy. The program will include a talk by Stephan A. Grupp, MD, PhD., Director of the Cancer Immunotherapy Program, director of
Translational Research for the Center for Childhood Cancer Research at Children&#146;s Hospital of Philadelphia and medical director of the Stem Cell Laboratory, Chief of the Section of Cellular Therapy and Transplant in the Hospital&#146;s Division
of Oncology, and members from CRISPR&#146;s senior management team. For more information on the investor event, please contact IR@crisprtx.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Poster
Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title: Production of site-specific Allogeneic CD19 CAR-T Cells by CRISPR-Cas9 for B-Cell Malignancies </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Location:</B> P181, Cellular Therapy Approaches Track </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date:</B> Friday November&nbsp;10, 2017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Time:</B> 12:30 PM
&#150; 2:00 PM ET </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CRISPR Therapeutics Investor Reception </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Location:</B> Gaylord Hotel at the Gaylord National Resort&nbsp;&amp; Convention Center </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date:</B> Friday November&nbsp;10, 2017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Time:</B> 6:00 PM
&#150; 8:00 PM ET </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Guest Speaker:</B> Stephan A. Grupp, MD, PhD, Director of the Cancer Immunotherapy Program, director of Translational Research for
the Center for Childhood Cancer Research at Children&#146;s Hospital of Philadelphia and medical director of the Stem Cell Laboratory, Chief of the Section of Cellular Therapy and Transplant in the Hospital&#146;s Division of Oncology<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A live webcast of the presentation, and the presentation materials, can be accessed under &#147;Events&nbsp;&amp; Presentations&#148; in the
Investors&nbsp;&amp; Media section of the Company&#146;s website at www.crisprtx.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CRISPR Therapeutics </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g489475g84u85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious
diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company&#146;s multi-disciplinary team of world-class researchers and drug
developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop
CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company&#146;s scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is
headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&amp;D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDIA CONTACTS: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Paganelli </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WCG on behalf of CRISPR </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 347-658-8290 jpaganelli@wcgworld.com
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Contact: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Erdman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">chris.erdman@crisprtx.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">617.307.7227 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Brinzey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke Partners for CRISPR </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">339-970-2843 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">chris.brinzey@westwicke.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g489475g84u85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g489475g84u85.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /2/B'\0_P#A SIH&E?;S>^9_P M_+V;-O\ LG.=WZ4 <?\
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M_H!H \Z_9_\ ^1!N_P#L(/\ ^BHZ!LS?CQ_R$O"'_7>7_P!"AH!'M% @H *
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M8HU8!23P0<C=CKCB@#G?[6^+]MX=C\2?;;.YT_R1<%!'&6\LC.2H4'IUP<T
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M%"\>!E-K@!?GZ<]#0!6\8Z#!X?O[>"&TU"S>2,M);WH5BA!QE9%^5U/7(Z4
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L_JW_ '^C_P#C= 7.U\(>$-/\%Z3+IVG37$L,DQG)N&5FW%57L!QA10(__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
